John Wiley & Sons Biopharmaceutics Modeling and Simulations Cover This book provides pharmaceutical professionals with essential tools for modeling biopharmaceutics. .. Product #: 978-1-118-02868-1 Regular price: $129.91 $129.91 Auf Lager

Biopharmaceutics Modeling and Simulations

Theory, Practice, Methods, and Applications

Sugano, Kiyohiko

Cover

1. Auflage September 2012
528 Seiten, Hardcover
Praktikerbuch

ISBN: 978-1-118-02868-1
John Wiley & Sons

Kurzbeschreibung

This book provides pharmaceutical professionals with essential tools for modeling biopharmaceutics. The author uses illustrations and practical problems rather than heavy math to explain the basics of modeling and simulation programs and how to apply them to different biopharmaceutical properties. Readers will find critical guidance on the design of drug formulations for achieving desired medicinal effects, including practical applications examples in drug research such as running and interpreting models, compound and formulation selection, mechanisms, and virtual clinical trials.

Weitere Versionen

epubmobipdf

A comprehensive introduction to using modeling and simulation programs in drug discovery and development

Biopharmaceutical modeling has become integral to the design and development of new drugs. Influencing key aspects of the development process, including drug substance design, formulation design, and toxicological exposure assessment, biopharmaceutical modeling is now seen as the linchpin to a drug's future success. And while there are a number of commercially available software programs for drug modeling, there has not been a single resource guiding pharmaceutical professionals to the actual tools and practices needed to design and test safe drugs.

A guide to the basics of modeling and simulation programs, Biopharmaceutics Modeling and Simulations offers pharmaceutical scientists the keys to understanding how they work and are applied in creating drugs with desired medicinal properties. Beginning with a focus on the oral absorption of drugs, the book discusses:
* The central dogma of oral drug absorption (the interplay of dissolution, solubility, and permeability of a drug), which forms the basis of the biopharmaceutical classification system (BCS)
* The concept of drug concentration
* How to simulate key drug absorption processes
* The physiological and drug property data used for biopharmaceutical modeling
* Reliable practices for reporting results

With over 200 figures and illustrations and a peerless examination of all the key aspects of drug research--including running and interpreting models, validation, and compound and formulation selection--this reference seamlessly brings together the proven practical approaches essential to developing the safe and effective medicines of tomorrow.

PREFACE xxv

LIST OF ABBREVIATIONS xxix

1 INTRODUCTION 1

1.1 An Illustrative Description of Oral Drug Absorption: The Whole Story 1

1.2 Three Regimes of Oral Drug Absorption 2

1.3 Physiology of the Stomach, Small Intestine, and Colon 5

1.4 Drug and API Form 6

1.5 The Concept of Mechanistic Modeling 7

References 8

2 THEORETICAL FRAMEWORK I: SOLUBILITY 10

2.1 Definition of Concentration 10

2.2 Acid-Base and Bile-Micelle-Binding Equilibriums 13

2.3 Equilibrium Solubility 19

References 31

3 THEORETICAL FRAMEWORK II: DISSOLUTION 33

3.1 Diffusion Coefficient 34

3.2 Dissolution and Particle Growth 36

3.3 Nucleation 56

References 61

4 THEORETICAL FRAMEWORK III: BIOLOGICAL MEMBRANE PERMEATION 64

4.1 Overall Scheme 64

4.2 General Permeation Equation 66

4.3 Permeation Rate Constant, Permeation Clearance, and Permeability 66

4.4 Intestinal Tube Flatness and Permeation Parameters 68

4.5 Effective Concentration for Intestinal Membrane Permeability 70

4.6 Surface Area Expansion by Plicate and Villi 71

4.7 Unstirred Water Layer Permeability 73

4.8 Epithelial Membrane Permeability (Passive Processes) 76

4.9 Enteric Cell Model 84

4.10 Gut Wall Metabolism 103

4.11 Hepatic Metabolism and Excretion 114

References 115

5 THEORETICAL FRAMEWORK IV: GASTROINTESTINAL TRANSIT MODELS AND INTEGRATION 122

5.1 GI Transit Models 122

5.2 Time-Dependent Changes of Physiological Parameters 127

5.3 Integration 1: Analytical Solutions 129

5.4 Integration 2: Numerical Integration 147

5.5 In Vivo FA From PK Data 150

5.6 Other Administration Routes 156

References 157

6 PHYSIOLOGY OF GASTROINTESTINAL TRACT AND OTHER ADMINISTRATION SITES IN HUMANS AND ANIMALS 160

6.1 Morphology of Gastrointestinal Tract 160

6.2 Movement of the Gastrointestinal Tract 170

6.3 Fluid Character of the Gastrointestinal Tract 178

6.4 Transporters and Drug-Metabolizing Enzymes in the Intestine 186

6.5 Intestinal and Liver Blood Flow 188

6.6 Physiology Related to Enterohepatic Recirculation 189

6.7 Nasal 191

6.8 Pulmonary 193

6.9 Skin 194

References 196

7 DRUG PARAMETERS 206

7.1 Dissociation Constant (pKa) 206

7.2 Octanol-Water Partition Coefficient 208

7.3 Bile Micelle Partition Coefficient (Kbm) 211

7.4 Particle Size and Shape 212

7.5 Solid Form 215

7.6 Solubility 223

7.7 Dissolution Rate/Release Rate 230

7.8 Precipitation 235

7.9 Epithelial Membrane Permeability 240

7.10 In Vivo Experiments 252

References 254

8 VALIDATION OF MECHANISTIC MODELS 266

8.1 Concerns Related to Model Validation Using In Vivo Data 267

8.2 Strategy for Transparent and Robust Validation of Biopharmaceutical Modeling 267

8.3 Prediction Steps 268

8.4 Validation for Permeability-Limited Cases 279

8.5 Validation for Dissolution-Rate and Solubility-Permeability-Limited Cases (without the Stomach Effect) 290

8.6 Validation for Dissolution-Rate and Solubility-Permeability-Limited Cases (with the Stomach Effect) 305

8.7 Salts 307

8.8 Reliability of Biopharmaceutical Modeling 311

References 311

9 BIOEQUIVALENCE AND BIOPHARMACEUTICAL CLASSIFICATION SYSTEM 322

9.1 Bioequivalence 322

9.2 The History of BCS 324

9.3 Regulatory Biowaiver Scheme and BCS 326

9.4 Exploratory BCS 335

9.5 In Vitro-In Vivo Correlation 335

References 338

10 DOSE AND PARTICLE SIZE DEPENDENCY 340

10.1 Definitions and Causes of Dose Nonproportionality 340

10.2 Estimation of the Dose and Particle Size Effects 341

10.3 Effect of Transporters 344

10.4 Analysis of In Vivo Data 345

References 346

11 ENABLING FORMULATIONS 347

11.1 Salts and Cocrystals: Supersaturating API 347


11.2 Nanomilled API Particles 358

11.3 Self-Emulsifying Drug Delivery Systems (Micelle/Emulsion Solubilization) 360

11.4 Solid Dispersion 363

11.5 Supersaturable Formulations 364

11.6 Prodrugs to Increase Solubility 365

11.7 Prodrugs to Increase Permeability 365

11.8 Controlled Release 366

11.9 Communication with Therapeutic Project Team 371

References 373

12 FOOD EFFECT 379

12.1 Physiological Changes Caused by Food 379

12.2 Types of Food Effects and Relevant Parameters in Biopharmaceutical Modeling 382

12.3 Effect of Food Type 398

12.4 Biopharmaceutical Modeling of Food Effect 401

References 403

13 BIOPHARMACEUTICAL MODELING FOR MISCELLANEOUS CASES 412

13.1 Stomach pH Effect on Solubility and Dissolution Rate 412

13.2 Intestinal First-Pass Metabolism 414

13.3 Transit Time Effect 415

13.4 Other Chemical and Physical Drug-Drug Interactions 415

13.5 Species Difference 417

13.6 Validation of GI Site-Specific Absorption Models 421

References 426

14 INTESTINAL TRANSPORTERS 430

14.1 Apical Influx Transporters 431

14.2 Efflux Transporters 435

14.3 Dual Substrates 438

14.4 Difficulties in Simulating Carrier-Mediated Transport 442

14.5 Summary 445

References 446

15 STRATEGY IN DRUG DISCOVERY AND DEVELOPMENT 452

15.1 Library Design 452

15.2 Lead Optimization 453

15.3 Compound Selection 455

15.4 API Form Selection 455

15.5 Formulation Selection 455

15.6 Strategy to Predict Human Fa% 456

References 457

16 EPISTEMOLOGY OF BIOPHARMACEUTICAL MODELING AND GOOD SIMULATION PRACTICE 459

16.1 Can Simulation be so Perfect? 459

16.2 Parameter Fitting 460

16.3 Good Simulation Practice 461

References 463

APPENDIX A GENERAL TERMINOLOGY 464

A.1 Biopharmaceutic 464

A.2 Bioavailability (BA% or F) 464

A.3 Drug Disposition 465

A.4 Fraction of a Dose Absorbed (Fa) 465

A.5 Modeling/Simulation/In Silico 465

A.6 Active Pharmaceutical Ingredient (API) 465

A.7 Drug Product 465

A.8 Lipophilicity 465

A.9 Acid and Base 466

A.10 Solubility 466

A.11 Molecular Weight (MW) 466

A.12 Permeability of a Drug 466

APPENDIX B FLUID DYNAMICS 468

B.1 Navier-Stokes Equation and Reynolds Number 468

B.2 Boundary Layer Approximation 469

B.3 The Boundary Layer and Mass Transfer 470

B.4 The Thickness of the Boundary Layer 470

B.5 Sherwood Number 471

B.6 Turbulence 473

B.7 Formation of Eddies 474

B.8 Computational Fluid Dynamics 474

References 476

INDEX 477
KIYOHIKO SUGANO has over seventeen years of experience as a pharmaceutical industrial researcher with Chugai in Japan and Pfizer in the United Kingdom. He has published extensively in peer-reviewed journals and book chapters, focusing on physicochemical profiling, drug permeability across biological membranes, oral drug delivery, and predictive and computational modeling.